Eli Lilly and Ypsome partner to advance automated insulin delivery system
pharmafile | November 20, 2020 | News story | Medical Communications |
Eli Lilly has entered into a global non-exclusive agreement with Ypsomed for the advancement of an automated insulin delivery system for people with diabetes.
Lilly will commercialise the system while Ypsomed will manufacture it. Called YpsoPum and available in 21 countries, it is a small device which utilises a touch screen to operate. Lilly will commercialise the pump in Europe, where it has been available since 2016, and in the US.
Marie Schiller, Vice President of Product Development for Connected Care and Insulins at Eli Lilly, said: “People who use insulin, along with their healthcare providers, need simple, effective tools that lead to improved outcomes, and Ypsomed is developing an automated insulin delivery system with several exciting features that can help meet that need.”
Ypsomed intends to submit an application with the FDA for the pump’s approval in 2022.
Simon Michel, CEO of Ypsomed, also commented on the new collaboration: “We are thrilled to partner with Lilly to bring our insulin pump to the US and deliver improved outcomes to people with diabetes through connected solutions. Managing diabetes with insulin is already complex enough, so we developed this insulin pump to be easy to learn and easy to operate.
“Our goal is to support people living with diabetes through app-centric insulin management, CGM data and advanced algorithms. Partnering with Lilly to bring a holistic platform to market is an important next step in this journey that started in 1984 by introducing the world’s first micro insulin pump to the market.”
This builds on Lilly’s recent work on tackling diabetes. In December 2019, the company signed a global commercialisation agreement with DexCom to integrate the latter’s products into its under-development personalised diabetes management system.
Conor Kavanagh
